Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cardiovascular & Renal Drugs Advisory Committee

Executive Summary

Centocor's ReoPro (abciximab) PLA (93-1057) will be reviewed for use in high-risk angioplasty during June 9 meeting. ReoPro (formerly CentoRx) is licensed to Lilly. Also on June 9, the committee will review Ciba-Geigy's NDA (20-364) for combination benazepril/amlodipine for treatment of hypertension. The product combines the active ingredients of Ciba's Lotensin and Pfizer's Norvasc and is being developed under a licensing agreement with Pfizer. On June 10, the committee will discuss an accelerated dosing schedule for Genentech's Activase ("The Pink Sheet" May 16, T&G-2). The meeting will take place at NIH's Masur Auditorium beginning at 9 a.m. both days
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel